Bastide Le Confort Médical (BLC) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
12 Nov, 2026Executive summary
Q1 FY2026-27 revenue €124.3m; organic growth 7.1% and reported growth 7.5%.
Financial highlights
Revenue was €124.3m versus €115.6m for Q1 FY2025-26 restated for discontinued operations; reported growth was 7.5%.
Outlook and guidance
FY2026-27 revenue target reiterated at ≥€500m, with operating margin to remain at the FY2025-26 level.
Continued cost control and operational efficiency initiatives; development strategy includes targeted external growth while maintaining a balanced financial structure.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Bastide Le Confort Médical
- Revenue grew 7.7%, margin reached 9.2% and net financial debt fell €134.7m.BLC
H2 2026 - Revenue up, margins improved, but net profit fell sharply due to higher costs and discontinued losses.BLCH2 23/24
- Revenue up 7.6% to €482.9M, margin target confirmed, leverage reduced post-EXPERF sale.BLCQ4 2026 TU
- Nine-month revenue grew 7.0% to €391.9M, led by home healthcare and respiratory segments.BLCQ3 2026 TU
- Net profit surged to €30.6M on 8% revenue growth and asset sales, leverage down to 2.77x.BLCH1 2026
- Revenue up 8% to €260.4M, with robust growth in home healthcare and respiratory segments.BLCQ2 2026 TU
- Q1 organic revenue up 8.3%, driven by home healthcare and respiratory growth.BLCQ1 2026 TU
- Strong revenue and margin growth, with improved leverage and positive 2025-2026 outlook.BLCH2 2025
- Revenue up 4.0% to €275.5M; record 9.1% margin; €375M refinancing secured.BLCH1 2025